19 results on '"Kishitani K"'
Search Results
2. Cognitive process produces inactivated serotonin
- Author
-
Kishitani, K., primary
- Published
- 1996
- Full Text
- View/download PDF
3. ANXIETY AND COGNITION
- Author
-
Kishitani, K., primary and Yuki, S., additional
- Published
- 1992
- Full Text
- View/download PDF
4. Concrete Pumping to the Tallest Structure in Japan
- Author
-
Kishitani, K., primary, Suzuki, T., additional, Watanabe, T., additional, Mihara, K., additional, Ishii, T., additional, and Kuwaharo, T., additional
- Published
- 1991
- Full Text
- View/download PDF
5. Durability of asphaltic materials
- Author
-
Hamada, M., Kishitani, K., and National Research Council of Canada. Division of Building Research
- Subjects
asphalt ,Voiries urbaines/chaussées ,insolation (sunshine) ,gel dégel ,asphalte (liant) ,freeze thaw cycles ,durability ,durabilité ,insolation (ensoleillement) ,Roads/Pavement ,résistance chimique ,chemical resistance - Abstract
The durability of asphaltic materials has been studied by the Organic Materials Section of the Division of Building Research and others for several years. Asphalt is one of the oldest engineering materials and since it is extensively used throughout the world it is also the subject of research by different organizations. This technical translation is a report of the work undertaken on this study in Japan. This report contains the results of the work of several research organizations after a six-year cooperative research programme under the direction of Prof. Hamada of Tokyo University. The results are divided into five sections, a general summary, and results of natural exposure, accelerated exposure, chemical resistance and freeze-thaw tests. Included in these are some interesting correlating studies between natural and accelerated weathering and between durability and the chemical and physical properties of the asphalts.
- Published
- 1964
6. Study on prevention of breakage in asphalt waterproofing
- Author
-
Hamada, M., Kishitani, K., Koike, M., Kariya, H., and National Research Council of Canada. Division of Building Research
- Subjects
asphalt ,Roofs ,ouvrage d'étanchéité ,couvertures ,breakage ,toiture ,Toits ,asphalte (liant) ,waterproofing works ,rupture (fracture) ,roofing - Abstract
This report of work undertaken in Japan contains results from three investigations, a field survey of leakage describing the types of failures encountered, a laboratory study to measure the engineering properties of the roofing membranes and an investigation to prevent breakage by using asphalts modified with rubber. This increases the breaking strain of the asphaltic membrane making it more able to withstand the strains of structural movements.
- Published
- 1964
7. Human Behaviour In Emergency Egress Of Building Fires
- Author
-
Yoon, M., primary, Sugahara, S., additional, and Kishitani, K, additional
- Published
- 1989
- Full Text
- View/download PDF
8. The rapid test JIS A 1804
- Author
-
Kishitani, K., Kobayashi, M., and Tamura, H.
- Published
- 1994
- Full Text
- View/download PDF
9. O-20-9 - Cognitive process produces inactivated serotonin
- Author
-
Kishitani, K.
- Published
- 1996
- Full Text
- View/download PDF
10. Integrated impact of multiple body composition parameters on overall survival in gastrointestinal or genitourinary cancers: A descriptive cohort study.
- Author
-
Sugawara K, Taguchi S, Gonoi W, Hanaoka S, Shiomi S, Kishitani K, Uemura Y, Akamatsu N, Inui S, Tanaka K, Yagi K, Kawai T, Nakagawa T, Fukuhara H, Abe O, Kume H, Gonzalez MC, Prado CM, and Seto Y
- Subjects
- Humans, Male, Female, Middle Aged, Retrospective Studies, Aged, Cohort Studies, Prognosis, Proportional Hazards Models, Survival Analysis, Intra-Abdominal Fat, Adult, Body Composition, Urogenital Neoplasms mortality, Muscle, Skeletal, Gastrointestinal Neoplasms mortality
- Abstract
Background: This study aimed to evaluate if combining low muscle mass with additional body composition abnormalities, such as myosteatosis or adiposity, could improve survival prediction accuracy in a large cohort of gastrointestinal and genitourinary malignancies., Methods: In total, 2015 patients with surgically-treated gastrointestinal or genitourinary cancer were retrospectively analyzed. Skeletal muscle index, skeletal muscle radiodensity, and visceral/subcutaneous adipose tissue index were determined. The primary outcome was overall survival determined by hospital records. Multivariate Cox hazard models were used to identify independent predictors for poor survival. C-statistics were assessed to quantify the prognostic capability of the models with or without incorporating body composition parameters., Results: Survival curves were significantly demarcated by all 4 measures. Skeletal muscle radiodensity was associated with non-cancer-related deaths but not with cancer-specific survival. The survival outcome of patients with low skeletal muscle index was poor (5-year OS; 65.2%), especially when present in combination with low skeletal muscle radiodensity (5-year overall survival; 50.2%). All examined body composition parameters were independent predictors of lower overall survival. The model for predicting overall survival without incorporating body composition parameters had a c-index of 0.68 but increased to 0.71 with the inclusion of low skeletal muscle index and 0.72 when incorporating both low skeletal muscle index and low skeletal muscle radiodensity/visceral adipose tissue index/subcutaneous adipose tissue index., Conclusion: Patients exhibiting both low skeletal muscle index and other body composition abnormalities, particularly low skeletal muscle radiodensity, had poorer overall survival. Models incorporating multiple body composition prove valuable for mortality prediction in oncology settings., (© 2024 The Author(s). Journal of Parenteral and Enteral Nutrition published by Wiley Periodicals LLC on behalf of American Society for Parenteral and Enteral Nutrition.)
- Published
- 2024
- Full Text
- View/download PDF
11. The importance of ethnic-specific cut-offs of low muscle mass for survival prediction in oncology.
- Author
-
Taguchi S, Sugawara K, Gonoi W, Hanaoka S, Shiomi S, Kishitani K, Uemura Y, Akamatsu N, Inui S, Tanaka K, Yagi K, Kawai T, Nakagawa T, Fukuhara H, Abe O, Seto Y, Gonzalez MC, Prado CM, and Kume H
- Subjects
- Humans, Prognosis, Muscle, Skeletal diagnostic imaging, Muscle, Skeletal pathology, Tomography, X-Ray Computed, Retrospective Studies, Sarcopenia etiology, Neoplasms complications
- Abstract
Background & Aims: While skeletal muscle index (SMI) is the most widely used indicator of low muscle mass (or sarcopenia) in oncology, optimal cut-offs (or definitions) to better predict survival are not standardized., Methods: We compared five major definitions of SMI-based low muscle mass using an Asian patient cohort with gastrointestinal or genitourinary cancers. We analyzed 2015 patients with surgically-treated gastrointestinal (n = 1382) or genitourinary (n = 633) cancer with pre-surgical computed tomography images. We assessed the associations of clinical parameters, including low muscle mass by each definition, with cancer-specific survival (CSS) and overall survival (OS)., Results: During a median follow-up period of 61 months, 303 (15%) died of cancer, and 147 died of other causes. An Asian-based definition diagnosed 17.8% of patients as having low muscle mass, while the other Caucasian-based ones classified most (>70%) patients as such. All definitions significantly discriminated both CSS and OS between patients with low or normal muscle mass. Low muscle mass using any definition but one predicted a lower CSS on multivariate Cox regression analyses. All definitions were independent predictors of lower OS. The original multivariate model without incorporating low muscle mass had c-indices of 0.63 for CSS and 0.66 for OS, which increased to 0.64-0.67 for CSS and 0.67-0.70 for OS when low muscle mass was considered. The model with an Asian-based definition had the highest c-indices (0.67 for CSS and 0.70 for OS)., Conclusions: The Asian-specific definition had the best predictive ability for mortality in this Asian patient cohort., (Copyright © 2023 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
12. Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
- Author
-
Taguchi S, Kawai T, Ambe Y, Kishitani K, Sugimoto K, Miyakawa J, Nakamura Y, Noda M, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Furuya Y, Sato Y, Uemura Y, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, and Kume H
- Subjects
- Humans, Platinum therapeutic use, Propensity Score, Urinary Bladder Neoplasms pathology, Carcinoma, Transitional Cell drug therapy
- Abstract
Objective: Enfortumab vedotin (EV) was approved for advanced urothelial carcinoma (UC) in 2021 after the EV-301 trial showed its superiority to non-platinum-based chemotherapy as later-line treatment after platinum-based chemotherapy and immune checkpoint inhibitors including pembrolizumab. However, no study has compared EV with rechallenging platinum-based chemotherapy (i.e., "platinum rechallenge") in that setting., Methods: In total, 283 patients received pembrolizumab for advanced UC after platinum-based chemotherapy between 2018 and 2023. Of them, 41 and 25 patients received EV and platinum rechallenge, respectively, as later-line treatment after pembrolizumab. After excluding two patients with EV without imaging evaluation, we compared oncological outcomes, including progression-free survival (PFS) and overall survival (OS), between the EV (n = 39) and platinum rechallenge groups (n = 25) using propensity score matching (PSM)., Results: Analyses on crude data (n = 64) showed no significant differences between the two groups regarding patients' baseline characteristics. PFS (5 months) and OS (11 months) in the EV group were comparable to those (8 and 12 months, respectively) in the platinum rechallenge group. After PSM (n = 36), the baseline characteristics between the two groups became more balanced, and PFS (not reached) and OS (not reached) in the EV group were comparable to those (8 and 11 months, respectively) in the platinum rechallenge group., Conclusions: EV and platinum rechallenge showed equivalent oncological outcomes, even after PSM, and both treatments should therefore be effective treatment options for post-platinum, post-pembrolizumab advanced UC., (© 2023 The Japanese Urological Association.)
- Published
- 2023
- Full Text
- View/download PDF
13. Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab.
- Author
-
Taguchi S, Kawai T, Buti S, Bersanelli M, Uemura Y, Kishitani K, Miyakawa J, Sugimoto K, Nakamura Y, Niimi F, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, and Kume H
- Subjects
- Humans, Antibodies, Monoclonal, Humanized therapeutic use, Prognosis, Retrospective Studies, Carcinoma, Transitional Cell drug therapy, Carcinoma, Transitional Cell pathology, Urinary Bladder Neoplasms drug therapy
- Abstract
Aim: To validate a 'drug score' that stratifies patients receiving immunotherapy based on concomitant medications (antibiotics/proton pump inhibitors/corticosteroids) in urothelial carcinoma (UC). Materials & methods: We assessed oncological outcomes according to the drug score in 242 patients with advanced UC treated with pembrolizumab. Results: The drug score classified patients into three risk groups with significantly different survivals. Heterogeneous treatment effect analyses showed that the primary cancer site (bladder UC [BUC] or upper-tract UC [UTUC]) significantly affected the prognostic capability of the drug score; it significantly correlated with survivals in BUC, while there were no such correlations in UTUC. Conclusion: A drug score was examined in advanced UC treated with pembrolizumab and was validated in BUC but not in UTUC.
- Published
- 2023
- Full Text
- View/download PDF
14. Surgical resection of retinoblastoma-associated bladder leiomyosarcoma during pregnancy: a case report.
- Author
-
Hoshina H, Taguchi S, Suyama H, Kishitani K, Akiyama Y, Yamada Y, Sato Y, Yamada D, Akiba N, Kumasawa K, Mori-Uchino M, Osuga Y, and Kume H
- Subjects
- Adult, Female, Humans, Pregnancy, Cesarean Section adverse effects, Cystectomy adverse effects, Urinary Bladder pathology, Pregnancy Complications, Neoplastic, Cancer Survivors, Neoplasm Metastasis, Leiomyosarcoma complications, Leiomyosarcoma surgery, Leiomyosarcoma diagnosis, Retinal Neoplasms pathology, Retinoblastoma pathology, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms surgery
- Abstract
Background: Management of a bladder tumor during pregnancy is an uncommon clinical situation. Leiomyosarcoma of the urinary bladder is a rare histological type of bladder tumor and a rare secondary cancer in survivors of retinoblastoma (RB). However, there has been no report of RB-associated bladder leiomyosarcoma during pregnancy., Case Presentation: A 37-year-old pregnant woman with a medical history of RB in infancy presented with gross hematuria at the 17
th week of gestation. Cystoscopy revealed a 40-mm papillary tumor on the left lateral wall of the urinary bladder. At the 25th week of gestation, she underwent transurethral resection of the bladder tumor, and the pathological diagnosis was bladder leiomyosarcoma with loss of RB1 expression. At the 31st week of gestation, she gave birth by caesarean section. One month after the delivery (to allow for involution of the uterus), she underwent partial cystectomy, and the specimen contained no residual leiomyosarcoma tissue., Conclusions: We have reported a case of RB-associated bladder leiomyosarcoma that was successfully treated during and after pregnancy., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
15. Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020).
- Author
-
Taguchi S, Kawai T, Nakagawa T, Miyakawa J, Kishitani K, Sugimoto K, Nakamura Y, Kamei J, Obinata D, Yamaguchi K, Kaneko T, Yoshida K, Yamamoto S, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Matsumoto A, Uemura Y, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Ishikawa A, Tanaka Y, Nagase Y, Fujimura T, Fukuhara H, Takahashi S, and Kume H
- Subjects
- Humans, Propensity Score, Retrospective Studies, Cohort Studies, Carcinoma, Transitional Cell pathology, Urinary Bladder Neoplasms pathology
- Abstract
Objectives: Although the treatment strategy for advanced urothelial carcinoma (aUC) has drastically changed since pembrolizumab was introduced in 2017, studies revealing current survival rates in aUC are lacking. This study aimed to assess (1) the improvement in survival among real-world patients with aUC after the introduction of pembrolizumab and (2) the direct survival-prolonging effect of pembrolizumab., Methods: This multicenter retrospective study included 531 patients with aUC undergoing salvage chemotherapy, including 200 patients treated in the pre-pembrolizumab era (2003-2011; earlier era) and 331 patients treated in a recent 5-year period (2016-2020; recent era). Using propensity score matching (PSM), cancer-specific survival (CSS) and overall survival (OS) were compared between the earlier and recent eras, in addition to between the recent era, both with and without pembrolizumab use, and the earlier era., Results: After PSM, the recent era cohort had significantly longer CSS (21 months) and OS (19 months) than the earlier era cohort (CSS and OS: 12 months). In secondary analyses using PSM, patients treated with pembrolizumab had significantly longer CSS (25 months) and OS (24 months) than those in the earlier era cohort (CSS and OS: 11 months), whereas patients who did not receive pembrolizumab in the recent era had similar outcomes (CSS and OS: 14 months) as the earlier era cohort (CSS and OS: 12 months)., Conclusions: Patients with aUC treated in the recent era exhibited significantly longer survival than those treated before the introduction of pembrolizumab. The improved survival was primarily attributable to the use of pembrolizumab., (© 2022 The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Urological Association.)
- Published
- 2022
- Full Text
- View/download PDF
16. Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma.
- Author
-
Sugimoto K, Taguchi S, Kishitani K, Kawai T, Masuda K, Nakamura Y, Kinjo M, Tambo M, Miyakawa J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Nakagawa T, Fukuhara H, and Kume H
- Subjects
- Humans, Cisplatin, Carboplatin adverse effects, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Gemcitabine, Carcinoma, Transitional Cell drug therapy, Urinary Bladder Neoplasms pathology
- Abstract
Background: While gemcitabine/cisplatin (GC) is the gold standard regimen for patients with advanced urothelial carcinoma (aUC), either dose-reduced GC or gemcitabine/carboplatin (GCa) is an alternative option for "cisplatin-unfit" patients. However, few studies have compared outcomes with these commonly used regimens in the real-world setting., Methods: We retrospectively reviewed patients with aUC who received full-dose GC, dose-reduced GC, or GCa as first-line salvage chemotherapy at two university hospitals between 2016 and 2020. Progression-free survival, cancer-specific survival, and overall survival, as well as best overall response and adverse event profiles, were compared among these three regimens., Results: Of 105 patients, 41, 27, and 37 patients received full-dose GC, dose-reduced GC, and GCa, respectively. Significant differences were noted in the patients' baseline age, primary site, and renal function among the three regimens. Sixty-nine (65.7%) patients died during a median follow-up period of 14 months. There was no significant difference among the three regimens for all survival outcomes and best overall response. However, the complete response rate of dose-reduced GC (2/27, 7.4%) appeared inferior to that of full-dose GC (9/41, 22.0%) or GCa (6/37, 16.2%). Regarding adverse event profiles, no significant difference was observed among the three regimens, except for significantly fewer cases with elevated alanine aminotransferase in the GCa group compared with the other groups., Conclusions: This study compared the oncological and toxicological outcomes of full-dose GC, dose-reduced GC, and GCa in real-world patients with aUC. Unlike in the clinical trial setting, there were almost no significant differences among the three regimens., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
17. Left-right reversal of the testes within the scrotum: An extremely rare variant of testicular ectopia.
- Author
-
Kishitani K, Yoda K, Taguchi S, Suyama H, Hoshina H, Akiyama Y, Yamada Y, Sato Y, Yamada D, and Kume H
- Abstract
Introduction: Testicular ectopia refers to abnormal positioning of testis, which includes a wide variety of variants. An ectopic testis is located off the normal path of male gonadal descent, unlike conventional undescended testis., Case Presentation: A 37-year-old man presented with the complaint of a palpable lesion in the scrotum. Magnetic resonance imaging of the scrotum revealed bilateral testes on the respective opposite sides of the scrotum with bilateral spermatic cords crossing under the base of the penis. Accordingly, he was diagnosed as "left-right reversal of the testes within the scrotum." In retrospect, the "palpable" lesion was thought to be the spermatic cords crossing above the testes. Semen analysis identified deteriorated sperm motility, suggesting possible male infertility., Conclusion: This case of left-right reversal of the testes within the scrotum is probably a new variant of testicular ectopia that has never been reported., Competing Interests: The authors declare no conflict of interest., (© 2022 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association.)
- Published
- 2022
- Full Text
- View/download PDF
18. A relationship between clomipramine brain concentration and its effect on serotonin metabolism.
- Author
-
Kurata K, Kurachi M, Kishitani K, Kido H, and Yamaguchi N
- Subjects
- Animals, Brain drug effects, Clomipramine analogs & derivatives, Clomipramine pharmacology, Dose-Response Relationship, Drug, Male, Rats, Rats, Inbred Strains, Receptors, Serotonin drug effects, Brain metabolism, Clomipramine pharmacokinetics, Serotonin metabolism
- Abstract
The relationship between clomipramine (CMP) brain concentration and its inhibitory effect on serotonin (5HT) turnover was investigated in rats treated with a single dose and multiple doses of CMP. CMP reduced the 5-hydroxyindole acetic acid (5HIAA) brain levels in two groups of rats. Concerning the 5HT turnover measured by the probenecid (PBC) technique, there were significant correlations between the CMP brain level (x) and 5HIAA brain level (y) after PBC injections in both acute and chronic experiments. The regression lines for the respective groups were y = 764 - 117 log x (r = 0.84, P less than 0.001) and y = 770 - 97.7 log x (r = 0.68, P less than 0.001). The regression coefficient for the acute experiment was greater than that for the chronic one (p less than 0.001), indicating a less dose-response in the latter. From these findings, the acute dosing with CMP seemed to reduce the 5HT turnover without reference to the dose but a prolonged administration seemed to vary in its effect. This may be due to a compensatory mechanism in the 5HT system induced by chronic CMP-treatment.
- Published
- 1988
- Full Text
- View/download PDF
19. A pharmacokinetic study of clomipramine in regions of the brain.
- Author
-
Kurata K, Kishitani K, Kido H, Kurachi M, and Yamaguchi N
- Subjects
- Animals, Blood-Brain Barrier, Clomipramine analogs & derivatives, Kinetics, Male, Rats, Rats, Inbred Strains, Brain metabolism, Clomipramine metabolism
- Abstract
The pharmacokinetic profiles of clomipramine (CMP) and the serial changes of its concentration in specific brain regions were investigated in rats after an acute treatment with intravenous CMP (10 mg/kg). The CMP concentrations in plasma declined triexponentially and fitted a three-compartment open model. The brain to plasma concentration ratio showed a constant value, 22.2 +/- 4.9, 30 minutes after the injection. Regional brain differences in the CMP distribution and accumulation were also found. Four hours after the injections, the hippocampus was found to have the highest drug concentration, and the concentrations in this region were in the following order; thalamus, striatum, amygdala, cortex greater than pons + medulla oblongata greater than hypothalamus, bulbus olfactorius + septum, mesencephalon greater than cerebellum. Particularly, unique kinetics were observed in the cortex, amygdala and hippocampus.
- Published
- 1986
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.